



Universiteit
Leiden
The Netherlands

Effects of inhaled corticosteroids on clinical and pathological outcomes in COPD - Insights from the GLUCOLD study

Kunz, L.I.Z.

Citation

Kunz, L. I. Z. (2016, November 30). *Effects of inhaled corticosteroids on clinical and pathological outcomes in COPD - Insights from the GLUCOLD study*. Retrieved from <https://hdl.handle.net/1887/44522>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/44522>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/44522> holds various files of this Leiden University dissertation.

Author: Kunz, L.I.Z.

Title: Effects of inhaled corticosteroids on clinical and pathological outcomes in COPD - Insights from the GLUCOLD study

Issue Date: 2016-11-30

CHAPTER 6



Airway Inflammation in COPD after Long-term Withdrawal of Inhaled Corticosteroids

A decorative pattern of blue leaves and leaf fragments is scattered across the lower half of the page, starting from the left margin and extending towards the right.

Lisette I.Z.Kunz, Nick H.T. ten Hacken, Thérèse S.Lapperre, Wim Timens,
Huib A.M. Kerstjens, Annemarie van Schadewijk, Judith M. Vonk, Jacob K. Sont,
Jiska B. Snoeck-Stroband, Dirkje S. Postma, Peter J. Sterk, Pieter S. Hiemstra
and the GLUCOLD study group

Eur Respir J, in revision

ABSTRACT

Background: Long-term treatment with inhaled corticosteroids (ICS) might attenuate lung function decline and decrease airway inflammation in a COPD subset, whereas ICS discontinuation relapses lung function decline. We hypothesized that airway inflammation increases after ICS withdrawal following long-term ICS treatment in COPD.

Methods: In the GLUCOLD-1 study (GL1) 114 patients with moderate to severe COPD were treated randomized to 6-month or 30-month fluticasone propionate (500µg bid), 30-month fluticasone/salmeterol (500/50µg, bid) or placebo. In the follow-up study (GL2), patients were followed prospectively for 5 consecutive years, treated by their physician. Bronchial biopsies and induced sputum were collected at baseline (GL1), 30-month (end GL1) and 7.5-year (end GL2) to assess inflammatory cell counts. Analysis was performed by linear mixed-effects models.

Results: In patients using ICS during GL1 and using ICS 0-50% of time during GL2 (n=61/85), bronchial cells increased in GL2 significantly: CD3⁺ (fold change/year GL2-GL1 [95%CI] 2.68 [1.87-3.84]), CD4⁺ (1.91 [1.33-2.75]), CD8⁺ cells (1.71 [1.15-2.53]) and mast cells (1.91 [1.36-2.68]). Additionally, sputum total cell counts increased significantly in GL2 (1.90 [1.42-2.54]), macrophage (2.10 [1.55-2.86]) neutrophil (1.92 [1.39-2.65]) and lymphocyte counts (2.01 [1.46-2.78]).

Conclusions: ICS discontinuation increases airway inflammation in moderate to severe COPD patients, suggesting that anti-inflammatory effects of ICS in COPD are not maintained after ICS discontinuation.

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic inflammation in the airways, with neutrophils, macrophages and CD8⁺ T-cells as major inflammatory cell types [1]. More severe airflow limitation is associated with more severe airway inflammation. As the progressive course of the disease continues to more severe airflow limitation, airway inflammation increases over time [2-4]. Except for smoking cessation, there is currently no therapy that halts the inflammatory process in the airways.

According to current guidelines, treatment with inhaled corticosteroids (ICS) is recommended for severe and very severe COPD patients in case of frequent exacerbations. Up to now only a few trials have evaluated the anti-inflammatory effect of ICS in bronchial biopsies and bronchoalveolar lavage (BAL) in COPD. A recent meta-analysis showed that 12- to 26-week ICS treatment in COPD reduced CD4⁺ and CD8⁺ cells in bronchial biopsies [5-10]. In addition, ICS reduced neutrophil and lymphocyte counts in BAL, but increased macrophage counts [9, 11-13]. Our study group has previously shown that 30-month treatment with inhaled fluticasone decreased the number of bronchial CD3⁺, CD4⁺, CD8⁺ cells and mast cells, and reduced the sputum neutrophil, macrophage and lymphocyte counts [8].

Discontinuation of ICS may increase the number of exacerbations [14-16] and accelerate lung function decline in patients with COPD [17-22]. However, little is known about the effect of ICS discontinuation on airway inflammation. An increase in percentage sputum neutrophils was found in COPD patients randomized to ICS withdrawal when compared to neutrophils in case of 6-week ICS continuation [23]. We previously showed that discontinuation after 6-month ICS increased bronchial CD3⁺ cells, mast cells and plasma cells at 2.5 years compared to continued therapy, without significant effect on sputum inflammatory cells [8]. However, the effects of withdrawal of ICS after long-term treatment on airway inflammation have not been investigated, but are highly relevant to evaluate the sustained reductions in bronchial inflammation and possible disease-modifying effects.

We hypothesized that inflammatory cell counts in bronchial biopsies and sputum increase after withdrawal of ICS in COPD patients who had previously been randomized to 30-month ICS treatment during 5 subsequent years of prospective follow-up. Additionally, we examined whether the changes in inflammation after ICS withdrawal were associated with

changes in lung function decline.

MATERIALS AND METHODS

Study design and participants

Patients of the GLUCOLD (Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease) study (GL1) were enrolled in the observational, follow-up study (GL2). Details of the study design were previously described [8, 21]. In short, in GL1 114 moderate to severe, steroid-naïve COPD patients were randomized to one of the four treatment arms, with Diskus dry-powder inhalers (GlaxoSmithKline, Zeist, The Netherlands) each twice daily for 30 months: 1) fluticasone propionate (FP) 500µg (F30); 2) FP with salmeterol, 500/50µg, single inhaler (FS30); 3) 6-month FP followed by 24-month placebo (F6); and 4) placebo. During GL2, patients were treated by their own physician according to current guidelines [24], which implied that the majority of patients intermittently used or did not use ICS. At the end of GL2, a list of delivered medications was provided by the patients' pharmacy. The ethics committees of Leiden University Medical Center and University Medical Center Groningen approved both GL1 and GL2. Separate written informed consent for GL2 was provided by all patients.

Outcomes and measurements

The primary outcome of the present study was the effect of ICS withdrawal on inflammatory cell counts in the lamina propria of bronchial biopsies. Therefore, a fiberoptic bronchoscopy was performed after 5 years of follow-up (GL2) according to standardized protocols, consistent with bronchoscopies in GL1 [25]. Processing of bronchial biopsies was performed according to present recommendations [26], and two biopsies per patient were selected based on the largest lamina propria by evaluation of hematoxylin-eosin stained sections. Immunohistochemical stainings on 4µm sections of paraffin-embedded bronchial biopsies were performed with specific antibodies against T-lymphocytes (CD3, CD4, and CD8), macrophages (CD68), neutrophil elastase (NE), mast cell tryptase (AA1) and eosinophils (EG2), according to the previous protocols [25]. Due to a lack of significant ICS-induced changes in plasma cells in GL1, we did not include these cells in our current analysis. Bronchial cells were counted using image analysis software (ImageJ, version 1.48i, National Institutes of Public Health). Subepithelial cells were calculated as weighted means and expressed as number of cells per 0.1mm². The minimal selected area of lamina propria for analysis per biopsy was 0.02mm². Data from bronchial cell counts of baseline and after 30 months (GL1) were

previously reported [8].

The secondary outcome was the effect of ICS discontinuation on inflammatory cell counts in induced sputum. A sputum induction was performed at year two and five of GL2. For safety reasons, sputum was only induced in patients with a post-bronchodilator $FEV_1 \geq 1.2$ l. Induced sputum was processed according to the full sample method [27]. Two cytopsins per sample were stained with May-Grünwald Giemsa (MGG) to obtain differential cell counts. A sputum sample was considered adequate if $\leq 80\%$ squamous cells were present. Differential cell counts were expressed as cell count per 10^6 ml non-squamous nucleated cells. Sputum cell counts at baseline and after 30 months (GL1) were previously reported [8].

Statistical analysis

Data from all patients were used for the analysis and the statistical analysis was performed with SPSS 22.0 software (SPSS Inc., Chicago, IL). Because there were no differences in inflammatory cell counts after 30 months of treatment in the F6 and placebo groups, and in the FS30 and F30 groups [8], we combined these to increase power into two groups: F6/placebo and FS30/F30. ICS use during GL2 was retrospectively divided into the following groups: patients who used ICS 0-50% or 50-100% of the time. For the analysis of GL2, we focused on those patients using 0-50% ICS during GL2, being the largest subgroup (61 out of 85 patients). Based on the information of the patients' pharmacy, the daily dose of ICS (in μ g, in beclomethasone dipropionate [BDP] equivalents) during 5 years was calculated as daily sum of the different doses of ICS (in μ g/day) divided by the total time that ICS were used (days).

A linear mixed-effect model with a random intercept for each subject was applied, using all natural-log transformed inflammatory measurements from GL1 and GL2 as outcome variable and an identity covariance matrix. The analysis was stratified for original combined treatment groups and ICS use during GL2. The change in inflammatory cell counts in GL2 compared to GL1 (GL2 minus GL1) was assessed by two time variables in the models: time 1 (time since start of GL1: range 0-7.5 years) and time 2 (time since start of GL2: range 0-5 years; during GL1 this value is zero). To assess the change in cell counts between the original FS30/F30 groups compared to the original F6/placebo groups, a linear mixed-effect model with the same time variables was used including an interaction term between these time variables with the original combined treatment groups. Given the limited sample size of patients completing the 5 years of prospective follow-up, possible confounders (age, sex and center) were not included in the model. Smoking was unlikely to be a major confounder as shown in

a previous post-hoc analysis [8]. By Spearmans' correlation coefficient, we assessed whether the changes in inflammation in GL2 versus GL1 were associated with change in lung function in the same period.

Since the number of cells decreased during GL1 and increased at the end of GL2, and therefore represent a difference in slope, we calculated the rate of change. Therefore, data are presented as fold change per year between GL2 minus GL1 with 95% confidence interval (CI), calculated by taking the antilog of estimates from the linear mixed-effects models. Statistical significance was inferred at $P \leq 0.05$.

Table 1. Patient characteristics at baseline of randomized treatment (GL1) and at the start of 5 years of follow-up (GL2) for the original FS30/F30 and F6/placebo groups.

	Baseline GL1		Start of GL2	
	F6/placebo (n=60)	FS30/F30 (n=54)	F6/placebo (n=46)	FS30/F30 (n=46)
Gender (M/F) (n)	51/9	48/6	41/5	42/4
Age (yr)	61 (7.7)	62 (7.8)	64 (7.7)	64 (7.3)
Smoking (y/n) (n)	36/24	36/18	22/24	26/20
Packyears (yr)	41 (31-54)	47 (31-56)	43 (31-58)	49 (34-57)
Post-bronchodilator FEV₁ (% pred)	64 (8.3)	62 (9.3)	61 (11.1)	63 (11.7)
Post-bronchodilator FEV₁ (L)	2.05 (0.5)	2.06 (0.4)	1.92 (0.6)*	2.03 (0.5)
Post-bronchodilator FEV₁/IVC (%)	49 (8.5)	47 (8.6)	46 (10.6)	47 (9.9)

Data of the 2 combined groups are derived from the original 4 treatment groups in GL1 are presented as means and standard deviation, median with interquartile range (packyears) or numbers. F6: 6 months treatment with fluticasone, followed by 24 months of placebo; FS30: 30 months treatment with fluticasone and salmeterol; F30: 30 months treatment with fluticasone. Data for the individual 4 treatment groups have been previously reported [21].


* $P \leq 0.001$ compared to original combined F6/placebo groups at baseline GL1 (calculated with paired samples T-test).

RESULTS

Data from 114 patients were used for the analysis of GL1, 92 patients completed GL1, 85 patients started and 61 completed GL2 [8, 21]. Patient characteristics at both baseline and at start of GL2 were similar among the original combined treatment groups, except for post-bronchodilator FEV₁, which was significantly lower at the start of GL2 in the original combined F6/placebo groups compared to the original combined FS30/F30 groups (Table 1).

Most patients (61/85) used ICS 0-50% of time during GL2, with a mean daily ICS dose of 1019µg (SD 554µg) in BDP equivalents during GL2 (Table 2), which was not significantly different between the original combined treatment groups. Bronchial biopsies of 29 patients were available at the end of GL2 (Table 3), and 21 of these 29 patients used 0-50% of time ICS during GL2. Sputum samples suitable for analysis were available from 47 and 33 patients after 2 and 5-year follow-up, respectively (Table 3). A diagram with the number of patients per group and available number of samples is presented in Figure 1.

Figure 1: Diagram presenting the number of patients and available bronchial biopsies and sputum samples in GL1 and GL2 in the original combined treatment groups.



GL1: GLUCOLD 1 study, first part of the study. GL2: GLUCOLD 2 study, follow-up study. F6: 6 months treatment with fluticasone, followed by 24 months of placebo; FS30: 30 months treatment with fluticasone and salmeterol; F30: 30 months treatment with fluticasone.

Table 2: Number of patients at the start of the GLUCOLD follow-up study (GL2) using ICS and daily dose of ICS (in µg) during 5 years in those patients who used ICS during GL2.

Original treatment group	No ICS use (n)	≤50% use of ICS (n)	>50% use of ICS (n)	100% use of ICS (n)	Daily dose ICS (µg)
F6/placebo	20	12	10	1	875 (479)
FS30/F30	15	14	8	5	1141 (591)
Total	35	26	18	6	1019 (554)

The daily dose of ICS (in µg, in BDP equivalents) during 5 years was calculated by the sum of the different doses of ICS per day (in µg/day), divided by the total time that ICS were used (in days). Doses were based on data provided by the patients' pharmacy.

Daily dose of ICS is presented as means with standard deviations. F6: 6 months treatment with fluticasone and 24 months with placebo; FS30: 30 months treatment with fluticasone and salmeterol; F30: 30 months treatment with fluticasone.

Bronchial biopsies

Compared to GL1, patients within the combined original FS30/F30 groups, who used ICS 0-50% of time during GL2 showed an increase in bronchial CD3⁺ [GL2-GL1, expressed a fold change/year: 2.68 (1.87-3.84); P<0.001], CD4⁺ [1.91 (1.33-2.75); P=0.001], CD8⁺ cells [1.71 (1.15-2.53); P=0.008] and mast cells [1.91 (1.36-2.68); P<0.001] at the end of GL2 (Figure 2). Discontinuation of ICS or use of ICS 0-50% of time during GL2 in the original combined FS30/F30 groups increased the number of CD3⁺ cells (expressed as fold change/year) [1.78 (1.21-2.64); P=0.04], CD8⁺ cells [1.73 (1.05-2.85); P=0.033] and mast cells [1.52 (1.06-2.17); P=0.023] compared to the original combined F6/placebo groups.

Table 3: Sputum samples and bronchial biopsies at year 2 and year 5 of GL2, presented by original combined treatment groups and use of ICS during GL2.

			No ICS use	<50% ICS use	>50% ICS use	100% ICS use	total
Sputum	Year 2	F6/placebo	10	10	3	1	24
		FS30/F30	8	7	5	3	23
	Year 5	F6/placebo	12	7	1	0	20
		FS30/F30	4	5	3	1	13
Bronchial biopsies	Year 5	F6/placebo	10	5	3	1	19
		FS30/F30	3	3	4	0	10

Sputum samples were collected from 63 and 51 patients after 2 and 5 years of follow-up (suitable for analysis 47 and 33), respectively. Data presented as number of samples.

GL2: follow-up study; ICS: Inhaled corticosteroids. F6: 6-month ICS followed by 24-month placebo. FS30: 30-month fluticasone with salmeterol; F30: 30-month fluticasone.




Figure 2: Geometric mean cell counts in bronchial biopsies (per 0.1 mm² lamina propria) for those patients who used ICS 0-50% of the time during GL2 in the original combined treatment groups FS30/F30 and F6/placebo. Error bars represent 95% confidence interval. Data of bronchial CD3⁺ cells (Figure 2A), CD4⁺ cells (2B), CD8⁺ cells (2C) and mast cells (2D) are presented. Data were calculated by taking the antilog of the means of natural log-transformed number of cells. The group of patients who used ICS 50-100% of time during GL2 was too small, and is therefore not shown in the figures.

Sputum

At the end of GL2, patients of the original FS30/F30 groups who used 0-50% of time during GL2 had a higher total sputum cell count [GL2-GL1, expressed as fold change/year: 1.90 (1.42-2.54); $P<0.001$], as well as higher counts of sputum macrophages [2.10 (1.55-2.86)]; $P<0.001$], neutrophils [1.92 (1.39-2.65)]; $P<0.001$] and lymphocytes [2.01 (1.46-2.78)]; $P<0.001$], at the end of GL2 compared to during GL1 (Figure 3). Discontinuation of ICS or use of ICS 0-50% of time during GL2 in the original combined FS30/F30 groups increased the total number of sputum cells (expressed as fold change/year) [1.66 (1.12-2.46); $P=0.012$], sputum neutrophils [1.68 (1.09-2.58); $P=0.018$], macrophages (1.90 [1.26-2.85]; $P=0.002$) and lymphocytes [1.73 (1.09-2.74); $P=0.020$] compared to the original combined F6/placebo groups.




Figure 3: Geometric mean sputum cell counts (x 10⁴ per ml) for original combined treatment groups FS30/F30 and F6/placebo. Error bars represent 95% confidence interval. Data of patients who used ICS 0-50% of the time during GL2 are presented for total sputum cells (Figure 3A), neutrophils (3B), macrophages (3C) and lymphocytes (3D). Data were calculated by taking the antilog of the means of natural log-transformed number of cells. The group of patients who used ICS 50-100% of time during GL2 was too small, and is therefore not shown in the figures.

Relation between lung function decline and inflammatory cells

The accelerated rate of decline in post-bronchodilator FEV₁ during GL2 was associated with an increase in sputum macrophages in patients of the original F530/F30 groups ($R_s = -0.63$, $P = 0.04$) and with a trend towards an increase in bronchial neutrophil counts ($R_s = -0.60$, $P = 0.07$) (Figures 4A and B, respectively).




Figure 4: Correlation between change (end GL2-end GL1) in post-bronchodilator FEV₁ (L) and change in natural log-transformed sputum macrophages (end GL2-end GL1, expressed as number of cells $\times 10^4$ per ml) (Figure 4A, left panel) and changes in natural log-transformed bronchial neutrophils (per 0.1mm^2 lamina propria, Figure 4B, right panel). Each dot represents a single patient.

DISCUSSION

The present study shows that withdrawal of ICS after previous long-term ICS treatment in patients with moderate to severe COPD, is accompanied with increased bronchial T-lymphocytes and mast cells as well as several sputum cell counts. In addition, we found an association between the accelerated rate of lung function decline and increase in sputum macrophages during GL2, and a trend with bronchial neutrophils. These results suggest that airway inflammation is suppressed during active treatment with ICS and might relapse after long-term discontinuation of ICS.

We observed that several inflammatory cells in bronchial biopsies and sputum significantly

increased during 5-year follow-up in patients with moderate to severe COPD who did not use or only intermittently used ICS after previous 30-month randomized ICS treatment. These unique data confirm and extend previous findings of our study group, showing that withdrawal of ICS after 6-month ICS treatment increases bronchial CD3⁺ cells, mast cells and plasma cells when followed up to 30 months compared to those who continued ICS therapy, without a significant effect on sputum inflammatory cells [8]. Another open-labelled pilot study with only 6-week ICS withdrawal showed an increase in the percentage of sputum neutrophils compared to ICS continuation [23]. Taken together, the present study provides novel data on a relapse of airway inflammation after prolonged ICS discontinuation with previous long-term ICS use in COPD.

In this longitudinal study, we found that lung function decline seems to be related to an increase in sputum macrophage counts in moderate to severe COPD patients, the majority being without ICS treatment. Furthermore, a trend for an association with higher bronchial neutrophils was found. A previous study showed that higher sputum neutrophils were associated with faster FEV₁ decline in patients with severe COPD using ICS [3]. Furthermore, a weak association between sputum percentage neutrophils and FEV₁ percentage predicted was found in a cross-sectional study [4]. These findings in sputum neutrophils are likely not only explained by differences in study design, but also by differences among the studies in number of patients, severity or phenotype of COPD, and duration of treatment and withdrawal of ICS. A recent study by Barnes et al. found that COPD patients treated with fluticasone and a high percentage blood eosinophils at baseline have a slower rate of FEV₁ decline compared to placebo treated patients [28]. However, we could not detect a relation between baseline blood eosinophilia and lung function decline during GL2 in those who stopped or continued using ICS during GL2. Taken together, until now, this is the only long-term study that suggests an association between lung function decline and change in inflammation after prolonged ICS withdrawal.

A strength of our study is the long-term follow-up with monitoring of lung function and availability of sputum and bronchial biopsies during 5-year follow-up. This is unique, since no previous studies had such a prolonged treatment period as well as long follow-up period with treatment according to the current guidelines in a real life setting. It needs to be noted that the effect of ICS withdrawal in the present study was more pronounced in bronchial biopsies than in sputum, stressing the importance to not only study sputum cell counts when investigating COPD. Nevertheless, our study has some limitations. First, expectedly, the number of patients that finished the complete study is limited, particularly when considering the original treatment groups separately. Therefore, we chose to combine the original FS30/

F30 and F6/placebo groups to increase power as there were no differences between the F6 and placebo groups at the start of the GL2 but only following first 6-months treatment during GL1. The small groups of patients from whom bronchial biopsies and sputum samples were available, make the correlation with lung function decline less strong. Despite these relatively low numbers, we still detected associations between clinical and histological outcomes. Second, GL2 was a prospective, (non-randomized) observational study and the majority of patients (61 of 85) discontinued their ICS or used 0-50% of time of observation ICS during GL2 (Table 2). Adherence to medication was not checked, reflecting daily practice. This could have led to a misclassification of ICS use during GL2 and therefore might have influenced our outcomes. Nevertheless, when only compliant patients during GL1 were included in the current analysis, similar results were found (data not shown). Due to the limited number of patients in whom a bronchoscopy was performed (Figure 1), a comparison between those with continuous ICS use versus ICS withdrawal during GL2 was not possible. Third, inflammatory cells were stained by immunohistochemistry with different batches of antibodies and counted using a different camera and image analysis software compared to GL1 [28]. We cannot rule out that these differences could have influenced our data. However, the bronchial inflammatory cell counts found in GL1 and GL2 were in a comparable range and cannot explain the observed difference found between and within the groups. Finally, bronchial inflammation is unequally distributed along the airways [29]. Since we were only able to collect samples from the central airways, the effect of ICS withdrawal in the small airways could not be investigated in this study. Taken into account these considerations, we are nevertheless confident that our data provide a novel view on relevant changes in airway inflammation after long-term cessation of prolonged ICS treatment.

How can we interpret our results? In the first part of the study (GL1), we found a reduction in bronchial inflammation and attenuation of lung function decline during 30-month ICS treatment in patients with moderate to severe COPD [8]. In the current study (GL2), we observed the expected opposite in that ICS withdrawal after previous long-term treatment resulted in an increase in CD3⁺, CD4⁺, CD8⁺ T-cells and mast cells in this selected group of patients, which further extends our previous observation that withdrawal of ICS relapses lung function decline [21]. The opposite outcome of ICS therapy in the first phase when compared to the effects of ICS withdrawal on airway inflammation in the second observational phase of our study can be regarded as a validation and strongly supports the plausibility of our findings. Taken together, our data suggest that during active treatment with ICS effects on lung function and inflammation are transient, without persistent disease modification.

During the past 25 years numerous studies have been published concerning the question whether or not ICS are beneficial in COPD patients [30]. Our study shows that in this group of moderate to severe COPD, patients experience transient positive effects on lung function and on airway inflammation during ICS therapy, which are not maintained after ICS withdrawal [21]. The present selection of COPD patients may be representative of a particular phenotype that is responsive to steroid treatment [31], in whom long-term ICS therapy may need to be continued to maintain the observed beneficial effects on the course of lung function and airway inflammation over time.

CONCLUSION

In conclusion, the present data indicate that ICS discontinuation during 5 years following 30 months use of ICS, in a group of moderate to severe COPD patients, induces a relapse in bronchial and sputum inflammatory cells which is partially accompanied by a more rapid decline in lung function. These data suggest that ICS do not have a sustained disease modifying activity after ICS withdrawal in this group of COPD patients which is in line with observations in asthmatic patients.

REFERENCES

1. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. *Lancet* 2011; 378 (9795): 1015-1026.
2. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 2004; 350 (26): 2645-2653.
3. Donaldson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR, MacCallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with copd*. *Chest* 2005; 128 (4): 1995-2004.
4. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. *Respir Res* 2010; 11 (1): 77.
5. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Int J Chron Obstruct Pulm Dis* 2012; 7: 587-595.
6. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK. Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease. *Am J Respir Crit Care Med* 2006; 173 (7): 736-743.
7. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The Effects of Inhaled Fluticasone on Airway Inflammation in Chronic Obstructive Pulmonary Disease: A Double-Blind, Placebo-controlled Biopsy Study. *Am J Respir Crit Care Med* 2002; 165 (12): 1592-1596.
8. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, Van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2009; 151 (8): 517-527.
9. Reid DW, Wen Y, Johns DP, Williams TJ, Ward C, Walters EH. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. *Respirology* 2008; 13 (6): 799-809.
10. Bourbeau J, Christodoulouopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. *Thorax* 2007; 62 (11): 938-943.
11. Verhoeven GT, Hegmans JPJ, Mulder PGH, Bogaard JM, Hoogsteden HC, Prins J-B. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. *Thorax* 2002; 57 (8): 694-700.
12. Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. *Respir Med* 2005; 99 (12): 153

- 1494-1500.
13. Thompson AB, Mueller MB, Heires AJ, Bohling TL, Daughton D, Yancey SW, Sykes RS, Rennard SI. Aerosolized Beclomethasone in Chronic Bronchitis: Improved Pulmonary Function and Diminished Airway Inflammation. *Am Rev Respir Dis* 1992; 146 (2): 389-395.
14. Schermer TRJ, Hendriks AJC, Chavannes NH, Dekhuijzen PNR, Wouters EFM, van den Hoogen H, van Schayck CP, van Weel C. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. *Prim Care Resp J* 2004; 13 (1): 48-55.
15. Jarad NA, Wedzicha JA, Burge PS, Calverley PMA. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. *Respir Med* 1999; 93 (3): 161-166.
16. Van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of Discontinuation of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease. *Am J Resp Crit Care Med* 2002; 166 (10): 1358-1363.
17. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EFM, Calverley PMA. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. *N Engl J Med* 2014; 371 (14): 1285-1294.
18. Van der Valk P, Monninkhof E, Van der Palen J, Zielhuis G, Van Herwaarden C. Effect of Discontinuation of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: The COPE Study. *Am J Resp Crit Care Med* 2002; 166 (10): 1358-1363.
19. Wouters EFM, Postma DS, Fokkens B, Hop WCJ, Prins J, Kuipers AF, Pasma HR, Hensing CAJ, Creutzberg EC. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. *Thorax* 2005; 60 (6): 480-487.
20. Calverley PMA, Spencer S, Willits L, Burge PS, Jones PW. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. *Chest* 2003; 124 (4): 1350-1356.
21. Kunz LIZ, Postma DS, Klooster K, Lapperre TS, Vonk JM, Sont JK, Kerstjens HAM, Snoeck-Stroband JB, Hiemstra PS, Sterk PJ. Relapse in FEV₁ decline after steroid withdrawal in copd. *Chest* 2015; 148 (2): 389-396.
22. Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). *Respir Res* 2014; 15: 77: 1-12.
23. Borrill Z, Roy K, Kolsum U, Southworth T, Vestbo J, Singh D. Seretide withdrawal increases airway inflammation in moderate COPD patients. *Eur J Clin Pharmacol* 2009; 65 (11): 1165-6.
24. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Resp Crit Care Med* 2007; 176 (6): 532-555.
25. Lapperre TS, Postma DS, Gosman MME, Snoeck-Stroband JB, ten Hacken NHT, Hiemstra PS,

- Timens W, Sterk PJ, Mauad T, on behalf of the GLUCOLD Study Group. Relation between duration of smoking cessation and bronchial inflammation in COPD. *Thorax* 2006; 61 (2): 115-121.
26. Hsia CCW, Hyde DM, Ochs M, Weibel ER. An Official Research Policy Statement of the American Thoracic Society/European Respiratory Society: Standards for Quantitative Assessment of Lung Structure. *Am J Resp Crit Care Med* 2010; 181 (4): 394-418.
27. in 't Veen JC, de Gouw HW, Smits HH, Sont JK, Hiemstra PS, Sterk PJ, Bel EH. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. *Eur Respir J* 1996; 9 (12): 2441-2447.
28. Sont JK, de Boer WI, van Schadewijk WA, Grunberg K, van Krieken JH, Hiemstra PS, Sterk PJ. Fully Automated Assessment of Inflammatory Cell Counts and Cytokine Expression in Bronchial Tissue. *Am J Resp Crit Care Med* 2003; 167 (11): 1496-1503.
29. Battaglia S, Mauad T, van Schadewijk AM, Vignola AM, Rabe KF, Bellia V, Sterk PJ, Hiemstra PS. Differential distribution of inflammatory cells in large and small airways in smokers. *J Clin Pathol* 2007; 60 (8): 907-911.
30. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2012; 7: CD002991.
31. van den Berge M, Steiling K, Timens W, Hiemstra PS, Sterk PJ, Heijink IH, Liu G, Alekseyev YO, Lenburg ME, Spira A, Postma DS. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. *Thorax* 2014; 69 (1): 14-23.